Fund HoldingsAisling Capital Management LP

Total Portfolio Value
$476.29M
Total Bought
$7.25M
Total Sold
$3.43M
Net Transaction
+$3.81M
Filing Period:
Securities
SharesValue ($K)
Q4 2025
Q1 2026
Change
Q4 2025
Q1 2026
Weight (%)
Change
Syndax Pharmaceuticals, Inc. (SNDX)(SNDX)1,316,8061,316,806027,66630,7616.46%+3,094
Monte Rosa Therapeutics Inc (GLUE)(GLUE)1,472,3311,555,664+83,33323,08625,5915.37%+2,505
Eupraxia Pharmaceuticals Inc. (EPRX)0325,000+325,00002,3530.49%+2,353
BridgeBio Oncology Therapeutics (BBOT)564,6251,018,018+453,3937,0699,1111.91%+2,042
Bicara Therapeutics Inc. (BCAX)568,919568,91909,57511,3162.38%+1,741
Biomea Fusion Inc (BMEA)2,048,7572,048,75702,5403,1350.66%+594
Scholar Rock Holding Corporation (SRRK)(SRRK)77,03177,03103,3933,7870.80%+394
Aclaris Therapeutics Inc (ACRS)434,455434,45501,3081,6290.34%+321
OnKure Therapeutics, Inc. (OKUR)88,60788,60702573670.08%+110
Marker Therapeutics, Inc. (MRKR)325,370325,37004854230.09%-62
Compass Pathways Plc (CMPS)(CMPS)1,198,4181,432,336+233,9188,2697,9211.66%-348
Urogen Pharma Ltd. (URGN)(URGN)108,000108,00002,5291,9420.41%-588
CalciMedica, Inc. (CALC)521,1140-521,1143,4340-3,434
BridgeBio Pharma Inc. (BBIO)(BBIO)5,089,6115,089,6110389,304377,95579.35%-11,350
Page 1 of 1